(UroToday.com) Pembrolizumab has shown activity in a study of heavily pretreated patients with PD-L1-positive advanced prostate cancer and in a study of PD-L1-positive or PD-L1-negative patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel who received more than one next-generation hormonal agent.1 Olaparib is a poly adenosine diphosphate ribose polymerase (PARP) inhibitor that has shown antitumor activity in mCRPC. In data previously reported from cohort A of the KEYNOTE-365 study, the combination of pembrolizumab plus olaparib was well tolerated and showed antitumor activity in docetaxel-pretreated patients with mCRPC. At the European Society of Medical Oncology – 2020 Virtual Congress (ESMO), Dr. Jose A. Arranz Arija and colleagues presented updated results of cohort A, including the time to symptomatic skeletal event, radiographic bone progression, and radiographic soft tissue progression.